Monte Rosa Therapeutics unveils MRT-6160 preclinical data showing disease inhibition in immune models

Traders Union
All News
Business & Wealth
Companies
MRT-6160 data reveal broad impact

Top Stories

Editors' Picks

Stocks

Crypto

Economics

Currencies

Commodities

Business & Wealth

Market Voices

01.07.2026

Monte Rosa Therapeutics unveils MRT-6160 preclinical data showing disease inhibition in immune models — MRT-6160 data reveal broad impact

Monte Rosa Therapeutics revealed new preclinical findings for MRT-6160 at the Newcastle International Therapeutic Tolerance Workshop. The company reported that MRT-6160, a first-in-class VAV1 MGD, successfully inhibited disease progression in various immune-mediated disease models.

These results indicate a broad therapeutic potential for MRT-6160 in addressing a range of immune-driven conditions. The presentation supports ongoing research momentum as Monte Rosa Therapeutics continues advancing the compound toward future clinical evaluation.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Earlier this year, Monte Rosa Therapeutics introduced MRT-8102, a NEK7-targeted molecular glue for the treatment of cardiovascular inflammation. The company has also highlighted its commitment to workplace inclusion during Pride Month celebrations. The recent preclinical data add to a series of research and corporate updates from Monte Rosa.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

Editor's Picks for You

Tokens without buyers: Why NFT marketplaces are shutting down

By Mikhail Vnuchkov
52 min ago

Tokens without buyers: Why NFT marketplaces are shutting down

Editors' Picks

Is it bad to be rich: Why billionaires are seen as villains

By Alena Volkova
3 hours ago

Is it bad to be rich: Why billionaires are seen as villains

Editors' Picks

What is a national blockchain network and does the world need one?

By Olena Litvinenko
Yesterday

What is a national blockchain network and does the world need one?

Editors' Picks

All Editors' Top Picks

Latest Monte Rosa News

Monte Rosa Therapeutics to present Phase 1 MRT-8102 data in CVD risk subjects

By Elena Nikulina
30.09.2026

Monte Rosa Therapeutics to present Phase 1 MRT-8102 data in CVD risk subjects

Companies

Monte Rosa Therapeutics launches patient dosing in MRT-2359 combination study for mCRPC

By Olga Shendetskaya
24.08.2026

Monte Rosa Therapeutics launches patient dosing in MRT-2359 combination study for mCRPC

Companies

Monte Rosa Therapeutics delivers second quarter financial results and advances pipeline momentum

By Ashutosh Sureka
06.08.2026

Monte Rosa Therapeutics delivers second quarter financial results and advances pipeline momentum

Companies

All Monte Rosa News

Mikhail Vnuchkov
52 min ago

Tokens without buyers: Why NFT marketplaces are shutting down

Alena Volkova
3 hours ago

Is it bad to be rich: Why billionaires are seen as villains

Olena Litvinenko
Yesterday

What is a national blockchain network and does the world need one?

Eugene Komchuk
Yesterday

CertiK expert: Hackers are winning the arms race for now

Dmytro Kharkov
Yesterday

Ledger’s spy chip scandal: Can hardware wallets still guard crypto’s cold storage?

Daria Chernytska
7 min ago

Tokenization connects traditional markets with digital assets, Gracy Chen notes

Elena Nikulina
12 min ago

Houston bitcoin mining center delayed by blown fuses, Javier Hermosa confirms

Mikhail Vnuchkov
12 min ago

Falling AI prices threaten debt sustainability, Joe Consorti argues

Igor Krasulya
17 min ago

U.S. natural gas price stays below $4 while managed-money net-short positions grow, Mike McGlone notes

Alena Volkova
22 min ago

Keith McCullough: Small cap index falls 0.5 percent, Quad2 drawdown reaches 8.9 percent from cycle peak

Top News

Igor Krasulya
33 min ago

Cathie Wood warns of risks in memory chip stocks

Cathie Wood warns of risks in memory chip stocks

Olga Shendetskaya
4 hours ago

Gold prices rise as Middle East tensions complicate Fed rate outlook

Gold prices rise as Middle East tensions complicate Fed rate outlook

Olga Shendetskaya
4 hours ago

Asian tech shares fall sharply as doubts grow over AI profits

Asian tech shares fall sharply as doubts grow over AI profits

Eugene Komchuk
5 hours ago

Bitcoin falls below $82,000 before recovering

Bitcoin falls below $82,000 before recovering

Andrey Mastykin
20 hours ago

Oil prices hit near two-week highs as Houthi strikes threaten Gulf shipping

Oil prices hit near two-week highs as Houthi strikes threaten Gulf shipping

Top 5 companies for you

United States

Live News

Anton Kharitonov
Now

EUR/USD remains under pressure as dollar strength and European risks weigh on the euro

Ivan Andriyenko
Now

Plus500 acquires Hedge Capital Markets to expand U.S. trading business

Eugene Komchuk
Now

Robbers steal nearly $800,000 from crypto trader in the UK

Pavlo Kot
Now

Binance to shut down mining pool in November after six years

Mykhailo Ihnatenko
Now

Ethereum price faces key 50 SMA test after another $822M liquidation wave

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.